Pradaxa, Eliquis antidotes post impressive new study data; Never mind taxes, Mylan wants U.S. to protect it from Teva;

@FiercePharma: ICYMI Friday: Biosimilar of Novartis' eye drug Lucentis launched in India. Report | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. FiercePharmaManufacturing feature | Follow @EricPFierce

@CarlyHFierce: ICYMI: Teva turns up the heat on Mylan, taking its stake past critical threshold. Article | Follow @CarlyHFierce

> Breakthrough anti-anticoagulants designed to counter the effects of Boehringer Ingelheim's Pradaxa, and Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) Eliquis, unveiled stellar Phase III data Monday. Report

> Mylan ($MYL) may have moved its headquarters overseas to win a tax break, but it still wants to be treated as a U.S. company--at least when it comes to fending off a takeover by Teva ($TEVA). Report

> GlaxoSmithKline ($GSK) unloaded two of its meningitis vaccines--Nimenrix and Mencevax--to Pfizer ($PFE) to satisfy antitrust worries after its buyout of Novartis' ($NVS) vaccines business. Report

> Eisai won a new FDA approval for its seizure drug Fycompa, in patients with primary generalized tonic-clonic (PGTC) seizures. Release

> A senior Merck ($MRK) scientist faces drug charges after receiving a home delivery of a chemical commonly used to make the club drug GHB, reports. Story

Medical Device News

@FierceMedDev: ICYMI from FierceDrugDelivery: Teva partners with Microchips Biotech to deliver drugs via wirelessly controlled implant. Article | Follow @FierceMedDev

@VarunSaxena2: FDA approves novel tongue sensor for the blind. ICYMI Friday | Follow @VarunSaxena2

@EmilyWFierce: Loaded up with debt from M&A binge, Valeant still needs more deals. More from FiercePharma | Follow @EmilyWFierce

> Foundation Medicine teams up with IMS Health for cancer precision medicine project. More

> Report: TAVR procedures seen to change cardiac care in the U.S. Story

Biotech News

@FierceBiotech: FierceBiotech Radio on GlaxoSmithKline rumors, Allergan's new identity and Axovant's IPO. Listen | Follow @FierceBiotech

@JohnCFierce: Anthem going after Cigna -- payer consolidation will increase pressure on U.S. drug pricing. NYT story | Follow @JohnCFierce

@DamianFierce: True Detective is terrible and I'm going to watch the whole season. I don't deserve to vote. | Follow @DamianFierce

> Breakthrough anti-anticoagulants from Boehringer, Portola post stellar PhIII data. Report

> Kite and bluebird join forces with some cutting-edge cancer tech. Story

> Biotech billionaire Soon-Shiong steers immuno-oncology player Conkwest to $172.5M IPO. Article

Animal Health News

> Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit. News

> Startup Rex clears $1M, starts hiring in KC Animal Health Corridor. More

> Zoetis to cut 165 workers from NJ headquarters as downsizing gets underway. Story

> Report: DNA-based injections to fuel growth of animal vaccines market. Item

> Vets and pharma execs gather in DC to trade notes on pets in cancer research. Article

Biotech IT News

> Pfizer's Lipset plots path to mainstream acceptance of experimental trial techs. News

> DIA starts with a flurry of hires, deals and product updates. Report

> GSK gives Altius $95M and a mission to hire computer scientists for 'living genome' research. More

> REMS website overhauled by FDA to simplify access to information. Story

> FDA digs into PatientsLikeMe's data to add patients' voices to safety monitoring. Article

Pharma Marketing News

> Social listening should be a no-brainer for pharma, study finds. Report

> It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA. Item

> AstraZeneca nabs top pharma ad award at Cannes amid slim product-specific field. Article

> Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More

> Pharma ad budgets to dip in 2016, but J&J, Pfizer, Roche and Novartis should still top $2B. Story

And Finally... New scripts for Gilead Sciences's ($GILD) hep C drug Harvoni have started to decelerate, analysts say. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.